Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Robert W. Baird

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]

Related Keywords

United States ,America ,Raymond James ,Pascal Deschatelets ,Davido Watson ,Robertw Baird ,Institutional Trading Of Apellis Pharmaceuticals ,Securities Exchange Commission ,Jennison Associates ,Goldman Sachs Group ,Apellis Pharmaceuticals Price Performance ,Citigroup ,Blackrock Inc ,Apellis Pharmaceuticals ,Apellis Pharmaceuticals Inc ,News Ratings For Apellis Pharmaceuticals Daily ,T Rowe Price Investment Management Inc ,Nasdaq ,Analyst Recommendations For Apellis Pharmaceuticals ,Vanguard Group Inc ,Pricet Rowe Associates Inc ,Get Free Report ,General Counsel David ,Exchange Commission ,Rowe Price Investment Management ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Reiterated Rating ,